Transglutaminase inhibition: A therapy to protect cells from death in neurodegeneration?
antonio martin
World journal of biological chemistry, 2012
View PDFchevron_right
Transglutaminase Inhibition as a Possible Therapeutic Mechanism to Protect Cells from Death in Neurological Disorders
Fabiana Luise
Journal of Biochemistry and Molecular Biology Research, 2018
View PDFchevron_right
Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Vittorio Gentile
Recent Patents on CNS Drug Discovery, 2013
View PDFchevron_right
Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage
Janusz Tucholski
Journal of Neurochemistry, 2006
View PDFchevron_right
DNA damage, neuronal and glial cell death and neurodegeneration
Ari Barzilai
Apoptosis, 2010
View PDFchevron_right
Treating Neurodegenerative Conditions Through the Understanding of Neuronal Apoptosis
Santosh D'Mello
Current Drug Target -CNS & Neurological Disorders, 2005
View PDFchevron_right
The role of transglutaminases in neurodegenerative diseases: overview
Thomas Jeitner
Neurochemistry International, 2002
View PDFchevron_right
Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation
C. Brancolini
Cell Death and Differentiation, 1999
View PDFchevron_right
Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species
Oskar Th Adolfsson
Journal of Biological Chemistry, 2010
View PDFchevron_right
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases
Vittorio Gentile
Amino Acids, 2013
View PDFchevron_right
Identification of brain substrates of transglutaminase by functional proteomics supports its role in neurodegenerative diseases
Isabelle Nondier
Neurobiology of disease, 2017
View PDFchevron_right
Transglutaminases, neuronal cell death and neural repair: implications for traumatic brain injury and therapeutics
Manuela Basso
Current Opinion in Neurology, 2019
View PDFchevron_right
Transglutaminase type II is involved in the pathogenesis of endotoxic shock
Loretta Tuosto
2008
View PDFchevron_right
Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway
Catarina Figueiredo
Journal of Neuroinflammation, 2008
View PDFchevron_right
Transglutaminase activation in neurodegenerative diseases
Nancy Muma
Future Neurology, 2009
View PDFchevron_right
Transglutaminase 2 in human diseases
Zsolt Sarang
BioMedicine, 2017
View PDFchevron_right
Possible role of the transglutaminases in the pathogenesis of alzheimer's disease and other neurodegenerative diseases
Vittorio Gentile
2011
View PDFchevron_right
Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Paula Moreira
Current Drug Target -CNS & Neurological Disorders, 2005
View PDFchevron_right
The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer’s Disease
Micha Wilhelmus
Cells
View PDFchevron_right
Improvement in inflammation is associated with the protective effect of Gly-Pro-Glu and cycloprolylglycine against Aβ-induced depletion of the hippocampal somatostatinergic system
Laura Frago
Neuropharmacology, 2019
View PDFchevron_right
Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease
Ashish Kumar
Experimental Neurology, 2012
View PDFchevron_right
Pathological glial reactions in neurodegenerative disorders: prospects for future therapeutics
Stefano Ferroni
Expert Review of Neurotherapeutics, 2003
View PDFchevron_right
Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies
benjamin drukarch
The Journal of Pathology, 2012
View PDFchevron_right
Up‐regulation of tissue‐type transglutaminase after traumatic brain injury
Kevin Wang
Journal of …, 2002
View PDFchevron_right
Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases
Micha Wilhelmus
European Journal of Pharmacology, 2008
View PDFchevron_right
Transglutaminase 2: A Novel Autoantigen in Canine Idiopathic Central Nervous System Inflammatory Diseases
Naoaki Matsuki
Journal of Veterinary Medical Science, 2012
View PDFchevron_right
Polyglutamine Genes Interact to Modulate the Severity and Progression of Neurodegeneration in Drosophila
Nancy Bonini
PLoS Biology, 2008
View PDFchevron_right
Transglutaminases and neurodegeneration
Boris Krasnikov
Journal of Neurochemistry, 2009
View PDFchevron_right
Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models
Micha Wilhelmus
Scientific reports, 2016
View PDFchevron_right